Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL: A Population-Based Tromsø Cohort
Pathogens · 17.07.2026 · 15 (7) · 747
DOI: 10.3390/pathogens15070747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, online erschienen am 17.07.2026. Verfasst von Sveinung Wergeland Sørbye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathology, University Hospital of North Norway, 9006 Tromsø, Norway. Hauptthemen laut MEDLINE: Papillomavirus Infections, RNA, Messenger, Oncogene Proteins, Viral, Uterine Cervical Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
HPV DNA-positive women with ASC-US/LSIL cytology constitute a heterogeneous triage group. We evaluated genotype-specific HPV E6/E7 mRNA testing with PreTect HPV-Proofer’7 in a population-based cohort from Tromsø and compared the findings descriptively with a previously published cohort from Bodø. This retrospective quality-assurance study included 1006 HPV DNA-positive women with ASC-US/LSIL cytology screened between 2019 and 2024, with linkage to regional pathology records through 31 December 2025. The assay detects E6/E7 mRNA from HPV16, 18, 31, 33, 45, 52, and 58. ASC-US/LSIL accounted for 42.5% of linked HPV DNA-positive women in Tromsø compared with 22.3% in Bodø. Among the mRNA-tested ASC-US/LSIL cohorts, mRNA positivity was similar (40.8% vs. 44.6%). In Tromsø, CIN2+ was recorded in 26.1% of mRNA-positive and 7.9% of mRNA-negative women (RR 3.31, 95% CI 2.41–4.55), whereas CIN3+ was recorded in 3.9% and 1.0%, respectively (RR 3.88, 95% CI 1.53–9.82). For CIN2+, sensitivity was 69.5%, specificity 64.4%, PPV 26.1%, and NPV 92.1%. Among HPV16/18 DNA-positive women, CIN2+ risk was 42.7% in mRNA-positive and 13.4% in mRNA-negative women. Simulated mRNA-guided referral reduced immediate colposcopy referrals by 59.2%. Genotype-specific mRNA testing provided clinically relevant risk stratification, with directionally similar patterns being observed in the Tromsø and Bodø cohorts; however, mRNA-negative women require structured surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pathology, University Hospital of North Norway, 9006 Tromsø, Norway.
- PreTect AS, 3490 Asker, Norway.
ORCID-Profile: Sveinung Wergeland Sørbye, Elin Richardsen
Zitieren
APA
Sørbye, S. W., Falang, B. M., Antonsen, M., & Richardsen, E. (2026). Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL: A Population-Based Tromsø Cohort. Pathogens, 15(7), 747. https://doi.org/10.3390/pathogens15070747
Vancouver
Sørbye SW, Falang BM, Antonsen M, Richardsen E. Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL: A Population-Based Tromsø Cohort. Pathogens. 2026;15(7):747. doi:10.3390/pathogens15070747
BibTeX
@article{Srbye2026,
author = {Sørbye, Sveinung Wergeland and Falang, Bente Marie and Antonsen, Mona and Richardsen, Elin},
title = {Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL: A Population-Based Tromsø Cohort},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {7},
pages = {747},
doi = {10.3390/pathogens15070747}
}
EUVIMED